Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein - Wikidata - awgldk - TriplyDB

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

http://www.wikidata.org/entity/Q33865376

about

High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.Clinical development of Ebola vaccines Alphavirus-based vaccines Ebola virus vaccines: an overview of current approaches Mouse models for filovirus infections A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections Replicon RNA Viral Vectors as Vaccines Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Ebola and Marburg virus vaccines.Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases.Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats.Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus Production of CCHF virus-like particle by a baculovirus-insect cell expression system.Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Analysis of linear B-cell epitopes of the nucleoprotein of ebola virus that distinguish ebola virus subtypes.Ebola virus-like particles protect from lethal Ebola virus infection.Alphavirus vectors and vaccination.Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.Alphavirus vectors for vaccine production and gene therapy.Advances in virus-like particle vaccines for filoviruses.Filovirus vaccines.Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines Alphavirus replicon approach to promoterless analysis of IRES elements.Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses The evolving field of biodefence: therapeutic developments and diagnostics.Prediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins.Filovirus-like particles as vaccines and discovery tools.Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses.Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.

P2860

Q21090030-313B351D-A780-41C5-9D2C-6BD998E20DC7 Q24796792-278C2F99-EABC-4B6C-96E8-E277016E0506 Q26775792-4DCC2135-16B9-4E68-89ED-12F926C64DF4 Q26994724-843A6B9B-63F7-4DC0-B791-D7C741C909FD Q26999232-352B655F-DE43-4768-893B-4EA0C42C7BB4 Q27011569-3F7F1709-0BAF-4F59-94E8-CBC7A862352B Q27484994-3C08916B-5448-4DD3-8AD8-91098E000A1F Q27485491-157F4548-20E6-4A89-9238-EE3D9B15C60E Q28076639-C59F540E-0A7B-46B8-894F-F46AABD722E2 Q28768041-A6D8FE9F-3B3B-44B8-BFF4-91852102BF4E Q29994671-81F03E20-7F86-4171-96F3-6B846CEA5178 Q30234637-BEBB2396-71E7-4BBB-B465-5F73855E43ED Q30382230-11E346A2-8F25-42A0-B51E-EE3D7759B350 Q33351971-96F85C08-BFB2-4F1F-B77B-BD46C4002C36 Q33715773-440621D0-24BC-4AAF-8712-F270C5481ABF Q34000122-1B903D77-1F68-4888-8351-2222AF31B0E5 Q34042423-49E672A8-B531-46CC-9748-F9918262D151 Q34123838-556478C7-825B-4483-8E3C-F2C144CD316B Q34220503-241E2B0E-F920-416B-890B-6F501C754198 Q34345308-75D60EFF-8B0B-429B-8234-8C52DCF408AA Q34440836-A6990368-0BE4-40C3-AB36-18E8D7C8DB30 Q34463780-243B4B8A-2A23-4C76-AC9A-0F7664C4A54E Q34579231-396C67CE-6749-4E41-8695-70E37B931131 Q34792924-27FA462E-AA46-4BF5-8924-BA26CE6757F9 Q34812016-5A1B601E-600E-46CD-9B6D-B2D3C4AA85DB Q34969474-2F388823-728F-4CBD-BC88-CDB1D5E6104A Q35194202-CBA1167F-B627-498F-AA8B-7981111206B5 Q35300029-02047E8C-AE15-451F-B090-BF3177D92568 Q35558539-259A7439-25BE-4ADA-B952-88814B1BBAB5 Q35635459-62870DFD-6A5E-432A-99BB-EE30BC90F0FF Q35828303-00137B56-D6DE-4E7C-9800-E4234BCF86DC Q35946943-56F932A0-2B3A-4996-B1B0-0BC393B66F22 Q36044109-952A9C67-15A2-499F-89B2-2AEAAB31C0DD Q36085668-A3B6B691-2B55-4BFF-9D6F-8B39C72713C5 Q36138983-E4CF30F5-907A-4704-B17C-38A59F0B8DC3 Q36198685-1D7FE142-0368-41AB-BE7A-AD89A0411A3E Q36362287-33611871-7B66-46D2-8769-547DB46563E6 Q36370336-19B38177-6FC3-4E33-AD8D-12D99CC8A195 Q36378625-102D43E1-C125-4743-B862-2A5B9242C0BA Q36482804-68A04239-DD7F-42B2-80FF-F0F3FF720052

P2860

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

http://www.wikidata.org/entity/Q33865376

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@ast

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@en

type

label

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@ast

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@en

prefLabel

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@ast

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@en

P1433

Q33865376-A7BB5136-10AB-4975-8AAD-3F8D6877BB46

P1476

Q33865376-EA0DA91A-D7B7-4F06-8398-09C4840F7355

P2093

Q33865376-CB9300F7-2774-4A3A-8E1A-91DB5BCEB1FF

Q33865376-DC8D771E-BFF1-4840-AB71-5E57AF00F7D7

P2860

Q33865376-17B5EB60-C560-4037-8068-22CFDE3C70C4

Q33865376-1E5B1309-CBB4-4571-AA7F-3EBCD9C4112A

Q33865376-229859FD-1429-437D-A587-045A188AB33B

Q33865376-2304B900-F0FF-429E-85D8-DB57BE5EBF13

Q33865376-38626747-A2EF-4443-955E-6E74670C616D

Q33865376-483EFD8C-D45C-4BFA-ACFB-42B23A7EDF31

Q33865376-578043F1-7E72-4DBC-B6C2-956972FB3082

Q33865376-5B8D6047-D354-4433-A631-67FB3F826709

Q33865376-602E23E5-7D41-4C05-BFBF-766843C45687

Q33865376-630C6999-3906-43EB-9B9F-F5DF0C183A76

P304

Q33865376-C43857F5-E76D-46BA-9348-DE7871F23A6D

P31

Q33865376-7C5517E4-59BC-48F1-BC97-FD5F9A33DF6B

P356

Q33865376-2D5E566B-3BAF-49E9-91EE-B48BFA98C3FE

P433

Q33865376-E6FF1DC0-87E7-48C0-8D55-8805F75F3605

P478

Q33865376-3FAF3B83-4736-4650-BB02-30F04FF5ED51

P577

Q33865376-7DB65660-4589-41B3-904A-9210D0840DA0

P5875

Q33865376-3C5183DF-2AF6-41DC-95A5-6D7C9028E1CC

P698

Q33865376-DDFDB0AD-1B97-4B6F-9BC1-610D0CF69FEA

P921

Q33865376-2DE810CB-6856-4DE1-8929-58C5875EE187

Q33865376-3677D06B-5622-45D5-A6BB-D7F1F856F856

Q33865376-F2BFBE87-FFC5-44D1-9C8E-0EBEF2E766F1

P932

Q33865376-C6ECEFFC-B51E-4932-924B-027BA8565496

P356

JVI.75.6.2660-2664.2001

P1433

Journal of Virology

P1476

Protection from Ebola virus me ...... ic for the viral nucleoprotein

@en

P2093

Hart MK

http://www.w3.org/2001/XMLSchema#string

Wilson JA

http://www.w3.org/2001/XMLSchema#string

P2860

Ebola haemorrhagic fever in Zaire, 1976

Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules.

Human asymptomatic Ebola infection and strong inflammatory response.

Immunization for Ebola virus infection.

The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit.

Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Plaque assay for Ebola virus.

P304

2660-2664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.75.6.2660-2664.2001

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12108108

http://www.w3.org/2001/XMLSchema#string

P698

11222689

http://www.w3.org/2001/XMLSchema#string

P921

Ebola nucleoprotein

P932

115890

http://www.w3.org/2001/XMLSchema#string